opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com
Company profile
Ticker
OPT, CKDXF
Exchange
Website
CEO
Megan Baldwin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
OPT stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Opthea to Participate in the 23rdAnnual Needham Virtual Healthcare Conference
4 Apr 24
6-K
Current report (foreign)
3 Apr 24
6-K
Current report (foreign)
19 Mar 24
6-K
Opthea to Participate in the Leerink Partners Global Biopharma Conference
6 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Opthea Reports Half-Year Financial Results and Business Updates
28 Feb 24
6-K
Current report (foreign)
20 Feb 24
6-K
Current report (foreign)
14 Feb 24
Latest ownership filings
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
REGAL FUNDS MANAGEMENT PTY LTD
14 Feb 24
SC 13G/A
Regal Partners Ltd
15 Feb 23
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
REGAL FUNDS MANAGEMENT PTY LTD
14 Feb 22
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 22
SC 13G
BAKER BROS. ADVISORS LP
16 Feb 21
SC 13G/A
REGAL FUNDS MANAGEMENT PTY LTD
10 Feb 21
SC 13G
REGAL FUNDS MANAGEMENT PTY LTD
12 Nov 20
Financial summary
Quarter (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
66.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 11.36 bn |
Total shares | 55.25 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Regal Funds Management PTY | 50.77 mm | $569.39 mm |
Baker Bros. Advisors | 2.69 mm | $7.54 bn |
Victory Capital Management | 961.49 k | $2.69 bn |
Teacher Retirement System Of Texas | 625.00 k | $1.75 mm |
Millennium Management | 163.81 k | $458.65 mm |
Laurion Capital Management | 22.65 k | $63.43 mm |
Jane Street | 10.93 k | $32.04 mm |
MS Morgan Stanley | 1.00 k | $2.80 mm |
Tower Research Capital | 81.00 | $227.00 k |
Proequities | 0.00 | $0.00 |
Press releases
Opthea Appoints John Han, PharmD, as VP Medical Affairs
8 Apr 24
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
4 Apr 24
Opthea Appoints Sujal Shah to the Board of Directors
3 Apr 24
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
19 Mar 24
Opthea to Participate in the Leerink Partners Global Biopharma Conference
5 Mar 24